Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + gemcitabine + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination regimen consists of toripalimab, a humanized IgG4 monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, administered in conjunction with the cytotoxic antimetabolites gemcitabine and 5-fluorouracil (5-FU). Toripalimab acts as an immune checkpoint inhibitor, preventing the interaction between PD-1 and its ligands (PD-L1 and PD-L2) to reactivate T-cell-mediated anti-tumor immunity. Gemcitabine and 5-fluorouracil are chemotherapeutic agents that interfere with DNA synthesis; gemcitabine inhibits ribonucleotide reductase and incorporates into DNA, while 5-fluorouracil inhibits thymidylate synthase. This specific triple-combination therapy is being investigated in a Phase II single-arm clinical trial sponsored by Jiangmen Central Hospital for the treatment of patients with unresectable advanced cholangiocarcinoma.
- Brand names
- Tuoyi
- Other names
- Toripalimab with Gemcitabine and 5-FUToripalimab + Gemcitabine + 5-FUToripalimab + Gemcitabine + 5-Fluorouracil
02
Targets
TS (Thymidylate synthase)DNARNR (Ribonucleotide reductase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on toripalimab + gemcitabine + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + gemcitabine + 5-fluorouracil.